Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03194152
Recruitment Status : Completed
First Posted : June 21, 2017
Last Update Posted : February 28, 2019
Sponsor:
Information provided by (Responsible Party):
Vasanti Malik, Harvard School of Public Health

Brief Summary:

This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes).

The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.


Condition or disease Intervention/treatment Phase
T2D Dietary Supplement: Peanut Dietary Supplement: Control Not Applicable

Detailed Description:

Emerging evidence has shown that peanut consumption has beneficial effects in modifying lipid profiles, glucose, and other cardiometabolic risk factors. During the last two decades, China has experienced a dramatic increase in T2D prevalence largely due to rapid social and economic growth. Peanuts are commonly consumed as snacks in China. However, there is limited evidence on the specific health benefits of peanuts as part of the Chinese habitual diet.

Clinical Study Protocol

Study diet Subjects will consume their habitual diet with the test snacks provided as roasted peanuts and rice flour snack bars twice a day during a mid- morning snack and mid -afternoon snack. Subjects in the peanut group will consume two serving of peanuts and subjects in the control group will consume isocaloric rice bars on a daily basis under on site supervision. Subjects will be instructed to maintain their habitual diet and physical activity. During the study period, body weight will be monitored routinely to ensure that baseline weight does not fluctuate by more than 1kg. Prior to day 1, day 42 and day 84, a three-day diet record will be administered to subjects to calculate basal energy intake.

Study design The study is a randomized, controlled, parallel-arm trial precedes by a 1-week run-in period with control treatment to assess compliance, acceptability and to determine baseline values.After the run-in period, participants will be randomized to either the control group or treatment group for three months. Each treatment phase will be 3 months in duration. At baseline, day 42 and day 84, clinical assessment (body weight, waist/hip circumference, blood pressure, pulse) will be preformed and blood samples will be collected. Urinary will be collected on baseline, day 42 and day 84. Fecal samples will be collected on baseline and day 84. Three days dietary records and appetite sensation ratings will be collected three times during the study (baseline, day 42 and day 84).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 238 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel design with two intervention arms
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effects of Peanut Consumption on Cardiovascular Disease Risk Factors and Gut Microbiota Among Adults in China: A Randomized Controlled Trial
Actual Study Start Date : October 24, 2017
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : March 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Peanut
Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
Dietary Supplement: Peanut
Dietary Supplement: Peanut

Experimental: Control
Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
Dietary Supplement: Control
Dietary Supplement: High carbohydrate snacks




Primary Outcome Measures :
  1. Blood glucose [ Time Frame: Blood glucose will be measured at day 84. ]
    glucose, insulin, HbA1c


Secondary Outcome Measures :
  1. Blood lipids level [ Time Frame: Blood lipids level will be measured at day 84. ]
    cholesterol and triglyceride levels

  2. Blood Inflammatory status [ Time Frame: Inflammatory biomarkers will be measured at day 84. ]
    Inflammatory biomarkers

  3. Assessment of appetite and other hunger sensations [ Time Frame: Appetite and other hunger sensations will be measured at day 84. ]
    Appetite and other hunger sensations will be assessed using visual analogue scales

  4. Microbiome [ Time Frame: Micriobiome will be measured at day 84. ]
    fecal microbiome (subset) A subset of study subjects will be measured for fecal microbiome functionality.

  5. Polyphenol metabolites [ Time Frame: Polyphenol metabolites will be measured at day 84. ]
    Urinary polyphenol metabolites (subset)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 20-65
  • Increased waist circumference : ≥ 90 cm for men and ≥ 80 cm for women

Plus 1 or more of the remaining criteria:

  • Elevated TG level ≥ 1.7 mmo/L
  • Reduced HDL-Cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women)
  • Fasting glucose ≥ 5.6 mmol/L
  • Systolic/diastolic blood pressure ≥ 130/85 mmHg.

Exclusion Criteria:

  • Taking lipid lowering medications
  • With known or unknown peanut allergy (or any peanut containing products)
  • Thyroid disease
  • Diabetes mellitus
  • Kidney disease
  • Liver disease
  • Cardiovascular disease or cancer
  • Pregnant or lactating women
  • Heavy alcohol consumption (>14 drinks/week)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03194152


Locations
Layout table for location information
China
Liang Sun
Shanghai, China, 200040
Sponsors and Collaborators
Harvard School of Public Health
Investigators
Layout table for investigator information
Principal Investigator: Xiaoran Liu, PhD Harvard School of Public Health

Layout table for additonal information
Responsible Party: Vasanti Malik, PI, Harvard School of Public Health
ClinicalTrials.gov Identifier: NCT03194152     History of Changes
Other Study ID Numbers: IRB17-0703
First Posted: June 21, 2017    Key Record Dates
Last Update Posted: February 28, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases